Strut Health: Patient Profiles That Should Avoid It (and What to Know Before Signing Up)

What Is Strut Health and How Does It Work?

Strut Health is an online-only, cash-pay medical platform founded to provide men with convenient access to treatments for ED, hair loss, and, more recently, peptide therapies. Patients complete an asynchronous intake questionnaire, which a licensed physician reviews before a prescription is issued or declined. There are no live video visits by default, and there is no insurance billing.

The Asynchronous Model: Convenience With Trade-Offs

The asynchronous model speeds up access. It also means no real-time clinical dialogue. For straightforward presentations, such as a healthy 35-year-old with situational ED and no comorbidities, the process is often adequate. For anyone with a complex medical history, the absence of a synchronous exam creates real gaps in clinical assessment.

The American Urological Association's 2018 ED guideline notes that a focused medical and sexual history, plus a physical examination, is the standard first step in evaluating erectile dysfunction. [1] Strut Health's intake form substitutes for that exam. Whether that substitution is acceptable depends entirely on the patient's risk profile.

Cash-Pay Pricing and What It Means for Follow-Up

Because the platform is cash-pay, patients who discontinue treatment also discontinue medical follow-up. There is no embedded care coordinator or automatic lab monitoring. For medications that carry monitoring requirements, such as finasteride, which has a known, though contested, post-finasteride syndrome signal, or compounded growth-hormone-releasing peptides that may affect fasting glucose, the absence of built-in lab review is a structural gap worth naming directly.

Who Should Not Use Strut Health for ED Medications

PDE5 inhibitors, sildenafil and tadalafil, are among the safest drug classes in outpatient medicine when used in appropriate patients. The word "appropriate" carries a lot of weight.

Cardiovascular Contraindications

The 2012 Princeton Consensus III panel, published in the Mayo Clinic Proceedings, stratified men with ED into low-, intermediate-, and high-cardiovascular-risk categories and issued explicit guidance: men in the high-risk category should defer sexual activity and PDE5 inhibitor therapy until their cardiac condition is stabilized. [2] High-risk conditions include:

• Unstable or refractory angina
• Uncontrolled hypertension (systolic >170 mmHg or diastolic >100 mmHg at rest)
• Recent myocardial infarction (within 2 weeks)
• High-risk arrhythmias
• Hypertrophic obstructive cardiomyopathy
• Moderate-to-severe heart failure (NYHA Class III or IV)

Strut Health's intake form asks about cardiac history. Whether every patient answers accurately, and whether the reviewing physician has enough clinical context to catch misclassified risk, is not auditable from the outside. Patients in any high-risk cardiovascular category should be working with a cardiologist, not a cash-pay telehealth platform, before starting a PDE5 inhibitor.

Nitrate Use: An Absolute Contraindication

Any patient taking organic nitrates in any form, including nitroglycerin, isosorbide mononitrate, or amyl nitrite ("poppers"), must not take sildenafil or tadalafil. The combination causes a synergistic drop in blood pressure that can be life-threatening. [3] This contraindication is not dose-dependent or time-limited. It is absolute. Patients who use nitrates and still want treatment for ED need a supervised, in-person evaluation to explore alternatives such as vacuum erection devices or penile injections.

Alpha-Blocker Interactions

Men taking alpha-blockers (tamsulosin, doxazosin, terazosin) for benign prostatic hyperplasia face a clinically significant additive hypotension risk with PDE5 inhibitors. The FDA label for tadalafil specifies a minimum 4-hour separation from alpha-blocker dosing and states that combination use requires caution. [4] This interaction is manageable under physician supervision, but it requires individualized dosing guidance, not a standardized questionnaire response.

Who Should Not Use Strut Health for Hair Loss Treatments

Strut Health offers finasteride (oral and topical), dutasteride (off-label), and minoxidil in various formulations. Each carries a distinct risk profile.

Finasteride and the Post-Finasteride Syndrome Debate

Finasteride 1 mg (Propecia) is FDA-approved for male-pattern hair loss. The drug inhibits 5-alpha-reductase type II, reducing scalp dihydrotestosterone (DHT) by approximately 60%. [5] The MPHL evidence is solid, but the safety picture around persistent sexual, neurological, and psychological adverse effects has become genuinely contested.

A 2017 cohort study published in PeerJ (N=11,909) found that men who took finasteride for androgenetic alopecia had a 4.8-fold higher odds of persistent erectile dysfunction lasting more than 90 days after drug discontinuation compared with unexposed controls. [6] The FDA added a post-marketing label update in 2012 acknowledging persistent sexual side effects. The agency has since logged more than 1,400 adverse event reports related to post-finasteride syndrome as of 2023. [7]

Patients who should avoid finasteride entirely include:

• Men with a personal or first-degree family history of depression or suicidal ideation (the drug may suppress neuroactive steroids including allopregnanolone)
• Men already experiencing sexual dysfunction
• Men who have previously had adverse reactions to 5-alpha-reductase inhibitors
• Men with hepatic impairment, since finasteride is hepatically metabolized

Dutasteride: Broader Inhibition, Longer Half-Life

Dutasteride inhibits both 5-alpha-reductase type I and type II. Its half-life is roughly 5 weeks, meaning adverse effects persist long after discontinuation. Strut Health offers dutasteride off-label for hair loss. Given the longer tissue exposure, any man who experienced adverse effects on finasteride has a higher risk of a prolonged adverse course on dutasteride, not a lower one.

Women of Reproductive Age

Finasteride and dutasteride are both Pregnancy Category X (now "contraindicated in pregnancy" under the PLLR labeling system). Both drugs cause feminization of a male fetus. Strut Health markets primarily to men, but the platform's expanding offerings and the presence of compounded formulations mean that women encountering the platform need to know these drugs are absolutely off-limits during pregnancy or in women who may become pregnant. [8]

Minoxidil Cardiac Considerations

Oral minoxidil, even at the low doses (0.625 mg to 2.5 mg) used for hair loss, causes measurable fluid retention and reflex tachycardia in some patients. A 2022 review in the Journal of the American Academy of Dermatology noted that periorbital edema occurred in roughly 6% of patients on low-dose oral minoxidil and tachycardia in 3 to 7%, with most events mild. [9] Men with pre-existing heart failure, significant left ventricular dysfunction, or pericardial effusion should not start oral minoxidil without cardiology clearance.

Who Should Not Use Strut Health for Peptide Therapies

This section carries the most regulatory complexity. Strut Health offers compounded peptides including BPC-157, PT-141, and previously compounds in the sermorelin/ipamorelin class. The regulatory field here is evolving, and not in patients' favor.

BPC-157: No FDA Approval, No Human Clinical Trials

BPC-157 (Body Protection Compound-157) is a pentadecapeptide fragment derived from human gastric juice. Animal data, primarily rodent models, suggest anti-inflammatory and tissue-repair effects. [10] There are zero completed Phase II or Phase III human clinical trials for BPC-157 listed on ClinicalTrials.gov as of January 2025. The FDA has not approved BPC-157 for any indication and, in a 2022 guidance update, flagged several peptides including BPC-157 as substances that raise "significant safety concerns" when used in compounded preparations outside of an IND. [11]

Patients who should be especially cautious include:

• Anyone with a history of malignancy. BPC-157 demonstrated pro-angiogenic effects in animal models, and its impact on tumor vascularity in humans is completely unknown.
• Pregnant or breastfeeding women
• Patients on anticoagulants (the peptide may modulate nitric oxide pathways and clotting factors in animal studies)
• Immunocompromised patients, where unvalidated injectable compounds carry infection risk

PT-141 (Bremelanotide): Real Drug, Real Interactions

PT-141 is actually FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women. The approved route is subcutaneous self-injection 45 minutes before anticipated sexual activity. [12] Compounded PT-141 from 503A pharmacies is not the same as Vyleesi, and the FDA's approved labeling specifically warns against use in patients with cardiovascular disease: in clinical trials, transient blood pressure increases of up to 6 mmHg systolic were observed, and 40% of participants experienced nausea. [12]

Patients with uncontrolled hypertension, recent cardiovascular events, or who are using medications that lower blood pressure should not use PT-141 without physician-level cardiac assessment that goes beyond an online form.

Growth Hormone Secretagogues and Metabolic Risk

Compounds such as sermorelin, ipamorelin, and CJC-1295 stimulate pituitary GH release. Elevated GH and IGF-1 levels can worsen insulin resistance, promote fluid retention, and potentially stimulate growth of pre-existing tumors. [13] Active malignancy is an absolute contraindication. Patients with type 2 diabetes or prediabetes need baseline and follow-up fasting glucose or HbA1c testing, which a cash-pay asynchronous platform is not structurally designed to prompt.

The HealthRX clinical team applies a four-gate screening framework before recommending any peptide platform to a patient: (1) verified absence of active or recent malignancy, (2) baseline metabolic labs including fasting glucose and IGF-1, (3) confirmed absence of cardiovascular contraindications to the specific compound, and (4) availability of synchronous physician follow-up at 30 and 90 days. Strut Health's asynchronous model satisfies gate 3 partially and gates 1, 2, and 4 inconsistently.

Is Strut Health Legitimate? What the Regulatory Record Shows

Strut Health operates legally. It uses licensed physicians in the states where it operates, it does not prescribe DEA Schedule II to IV controlled substances through its platform, and its compounding pharmacy partners are 503A-registered facilities regulated by state boards. That is the floor of legitimacy, not the ceiling.

BBB Status and Complaint Patterns

As of January 2025, Strut Health does not hold BBB accreditation. The company has a BBB profile with a small number of filed complaints, most of which center on billing disputes, delayed shipments, and difficulty reaching customer service rather than clinical harm. This is consistent with the complaint profile of most direct-to-consumer telehealth platforms. The absence of large-scale clinical harm complaints does not validate clinical quality. It reflects, at least partly, the fact that the drugs most commonly prescribed (sildenafil, tadalafil, finasteride, minoxidil) have been in wide use for decades and have well-understood, relatively low acute-harm profiles in healthy young men.

LegitScript and Pharmacy Verification

LegitScript is the verification body used by Google and major ad networks to certify online pharmacy legitimacy. Strut Health's certification status should be independently verified by patients at legit.script.com before engaging with the platform. Platforms that fill prescriptions through uncertified pharmacies, or through 503B outsourcing facilities for patient-specific compounds that should go through 503A facilities, operate in a legal gray zone with real patient-safety implications.

State Regulatory Considerations

Telehealth prescribing rules vary by state. Some states require a prior in-person relationship or a synchronous visit for an initial prescription. Patients should confirm that Strut Health's asynchronous model is compliant with their state's telehealth prescribing standards before relying on an issued prescription as definitively legal. The Federation of State Medical Boards maintains a telehealth policy resource that lists state-by-state requirements. [14]

Strut Health Complaints: What Patients Actually Report

The majority of documented complaints about Strut Health fall into three categories:

Fulfillment and Shipping Delays

Multiple consumer reviews reference delays of 10 to 21 days for compounded medications. Compounded formulations require batch testing and are not shelf-stocked, making some delay inherent. For acute-use medications like PT-141 or sildenafil, a 3-week delay is clinically irrelevant to patient safety but significant to patient satisfaction.

Prescription Declines Without Explanation

Some patients report that their consultation was declined without a clear clinical explanation. This is actually appropriate prescriber behavior when red flags are identified, but the asynchronous format means the patient receives a form response rather than a clinical dialogue about alternatives. A patient declined for finasteride due to a reported history of depression, for example, deserves a conversation about low-level laser therapy or topical minoxidil, not just a rejection email.

Follow-Up Access

Because the model is transactional, follow-up communication after the initial prescription is filled is inconsistent. Patients on finasteride who develop sexual side effects at 6 months, for example, may find the communication channel less responsive than expected for what is a medically significant adverse effect requiring prompt evaluation.

Comparing Strut Health to the Standard of Care

The American Academy of Dermatology's 2021 guidelines on androgenetic alopecia recommend a baseline discussion of side effects, documentation of sexual function, and follow-up assessment at 3 to 6 months for patients starting finasteride. [15] The AUA's ED guideline recommends a cardiovascular risk assessment before initiating PDE5 inhibitor therapy. [1]

Strut Health's model meets some of these standards for low-risk patients and misses them for higher-risk ones. That is not a condemnation of the platform. It is a statement about patient selection. The platform works as designed for its target user: a generally healthy adult male with a straightforward, low-risk presentation.

The problem arises when patients self-select into the platform without recognizing that they fall outside that target profile. A 52-year-old man with type 2 diabetes, hypertension managed with an alpha-blocker, and a family history of prostate cancer is not the right candidate for an asynchronous telehealth prescription for dutasteride and a peptide stack. He needs an in-person urologist, an endocrinologist, and current labs.

Clinical Red Flags: When to Stop and See a Specialist Instead

Before completing a Strut Health intake form, consider stopping and scheduling an in-person appointment if any of the following apply:

• Systolic blood pressure consistently above 160 mmHg
• Current nitrate use in any form
• Personal history of prostate cancer, breast cancer, or any active malignancy
• Current use of anticoagulants (warfarin, apixaban, rivaroxaban)
• Personal or family history of major depressive disorder or suicidal ideation
• Fasting glucose above 126 mg/dL or a known HbA1c above 6.5%
• Age <18 (Strut Health is for adults only; finasteride is not approved for pediatric use)
• Current or planned pregnancy, or female partners of reproductive age sharing medications

These are not edge cases. They represent a meaningful fraction of men in the demographic most likely to seek help for ED or hair loss.